Biogen And Genentech Seek FDA Nod For Rituxan (Pharmaceutical Business Review)
Genentech and Biogen Idec have filed two supplemental Biologics License Applications (sBLAs) to the US Food and Drug Administration (FDA) for the approval of Rituxan (rituximab) plus standard chemotherapy. Rituxan will be used for patients suffering from chronic lymphocytic leukemia (CLL).